Summarize, find key points, and more

Paul Oppold

Vice President, Investments And Head Of Corporate Development @ Roivant Sciences

About Paul Oppold

Paul Oppold serves as the Vice President of Investments and Head of Corporate Development at Roivant Sciences, a position he has held since 2024. He has extensive experience in the healthcare sector, having previously worked in various roles including CEO at Aruvant and Portfolio Manager at Point72.

Current Role at Roivant Sciences

Paul Oppold serves as Vice President, Investments and Head of Corporate Development at Roivant Sciences. He has held this position since 2024, contributing to the company's strategic initiatives in investments and corporate growth. His role involves leveraging his expertise in market analysis and financial modeling to drive business development within the pharmaceutical and biotech sectors.

Previous Experience at Roivant Sciences

Prior to his current role, Paul Oppold worked at Roivant Sciences as Vice President, Investments from 2018 to 2024. During this six-year tenure, he focused on investment strategies and corporate development, enhancing the company's portfolio and market position in the healthcare industry.

Leadership at Aruvant

In 2019, Paul Oppold briefly served as the CEO of Aruvant, where he led the organization for six months. His leadership during this period was focused on advancing the company's objectives in the healthcare sector while based in New York, NY.

Educational Background

Paul Oppold holds a Master of Science in Biomechanical Engineering from the University of Oxford, which he completed in 2000. He also earned a Bachelor of Science in Mechanical Engineering from the Massachusetts Institute of Technology in 1999. His educational background provides a strong foundation for his work in the healthcare industry.

Expertise in Healthcare Investments

Paul Oppold possesses extensive expertise in analyzing market fundamentals and modeling financial projections specifically within the healthcare sector. His in-depth understanding of scientific materials supports his role in business development and investments in the pharmaceutical and biotech industries.